Blood products, volume control, and renal support in the coagulopathy of liver disease.
Plasma-based products are commonly used in patients who have chronic liver disease to treat perceived coagulopathy despite unproven efficacy and potentially severe risks, such as transfusion-related acute lung injury, which carries a high mortality rate. Moreover, volume expansion may acutely worsen portal hypertension and increase bleeding from the collateral portal vascular bed. Although factor replacement therapy may be warranted in selected situations, its use should be restricted because of the limitations of target tests, such as international normalized ratio, which poorly reflects presence of bleeding diatheses in patients who have cirrhosis. Renal replacement therapies are frequent adjuncts in patients who have cirrhosis and are acutely decompensated, and may correct uremia-related bleeding diathesis and assist in controlling vascular volume, although they are generally limited to use as a bridge to liver transplantation. Novel extracorporeal therapies are emerging and may also have significant interaction with the hemostatic system. Volume contraction and blood conservation therapies are relatively new and promising approaches to reduce use of blood products in liver transplantation.
Argo
Curtis K
CK
University of Virginia, Department of Medicine, Division of Gastroenterology and Hepatology, Box 800708, Charlottesville, VA, USA. Electronic address: cka3d@virginia.edu.
Balogun
Rasheed A
RA
University of Virginia, Department of Medicine, Division of Nephrology, Charlottesville, VA, USA.
D001778:Blood Coagulation Disorders / Q000209:etiology* / Q000628:therapy*; D001803:Blood Transfusion; D001811:Blood Volume Determination; D006801:Humans; D019934:International Normalized Ratio; D008103:Liver Cirrhosis / Q000097:blood / Q000150:complications*; D010949:Plasma; D017582:Renal Replacement Therapy